In a milestone moment, ASX-listed diagnostics innovator Proteomics International Laboratories has achieved its first patent globally in Japan for its simple “traffic light” diagnostic blood test for endometriosis.
The decision will protect the company’s intellectual property rights for its PromarkerEndo technology in the world’s fourth-largest healthcare market until March 16, 2041.
